Cosmos Holdings Appoints Dr. Manfred Ziegler to its Advisory Board
CHICAGO, IL / ACCESSWIRE / July 22 , 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that it has appointed finance veteran Dr. Manfred Ziegler to the Company's Advisory Board.
Dr. Ziegler brings over 30 years of executive management, financial, and operational experience, as well as extensive expertise in mergers and acquisitions, with a particular focus on high-growth public and private companies. Notably, Dr. Manfred Ziegler served as Chief Executive Officer of CC Pharma, a leading German distributor of pharmaceutical and medical products into more than 24 countries. Dr. Ziegler was instrumental in the restructuring of CC Pharma and contributed to the acquisition of CC Pharma by Aphria (NYSE:APHA) in 2019. Before joining CC Pharma, Dr. Ziegler founded, built and managed several companies in the automotive, food and medical industries, both domestic and international. Currently, Dr. Manfred Ziegler is a managing director and founder of Conzima GmbH, a business management consultancy firm focused on restructuring and reorganizing business processes to improve operational efficiency. Dr. Ziegler received a degree in business administration from University of Mannheim.
Dr. Ziegler, commented, "I have worked closely with Greg Siokas for several years, and it is a great honor to join as an advisor at this exciting time for the Company. I look froward to bringing my operational and M&A experience to Cosmos, as well as partnering with its incredibly talented management team to build a leading, highly scalable international pharmaceutical and nutraceutical company."
Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated, "We are pleased to welcome Dr. Ziegler to our advisory board. He brings with him an impressive track record in corporate finance, strategic management as well as mergers and acquisitions, which should be invaluable as we continue to rapidly expand our global footprint through organic growth and accretive acquisitions. Additionally, we believe Dr. Ziegler's operational experience and large network of contacts will assist us in expanding our distribution network, as well as launching innovative pharmaceutical and nutraceutical products in new markets worldwide."
About Cosmos Holdings, Inc.
Cosmos Holdings Inc. (NASDAQ:COSM) is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. The group is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation". Cosmos Holdings Inc. is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the group is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Holdings Inc. is strategically focusing on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Holdings has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: [email protected]
SOURCE: Cosmos Holdings, Inc.
View source version on accesswire.com:
https://www.accesswire.com/709475/Cosmos-Holdings-Appoints-Dr-Manfred-Ziegler-to-its-Advisory-Board